{"slideshow_credits": null, "snippet": "Half of the 20 doctors who received the most money from Genentech to promote its drug Lucentis in 2013 were among the highest users of the drug in 2012, a federal database shows.", "abstract": "Federal database shows half of the 20 ophthalmologists who were paid the most money by drug maker Genentech to promote its product Lucentis in 2013 were also among highest users of drug in 2012; drug costs $2,000 a dose, and is seen as no more effective for wet macular degeneration than much cheaper Avastin; some doctors say choice between drugs was not simply matter of cost and is not illustrative or conflict of interest.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}, {"firstname": "Rachel", "role": "reported", "lastname": "ABRAMS", "rank": 2, "organization": ""}], "original": "By KATIE THOMAS and RACHEL ABRAMS", "contributor": "Agustin Armendariz contributed reporting."}, "web_url": "http://www.nytimes.com/2014/12/08/business/paid-to-promote-eye-drug-and-prescribing-it-widely-.html", "lead_paragraph": "Half of the 20 doctors who received the most money from Genentech to promote its drug Lucentis in 2013 were among the highest users of the drug in 2012, a federal database shows.", "headline": {"main": "Paid to Promote Eye Drug, and Prescribing It Widely", "print_headline": "Paid to Promote Eye Drug, and Prescribing It Widely"}, "_id": "5484fc3f38f0d84e18ddfae6", "word_count": "1475", "multimedia": [{"height": 126, "url": "images/2014/12/08/business/08EYE/08EYE-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/12/08/business/08EYE/08EYE-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 1464, "url": "images/2014/12/08/business/08EYE/08EYE-articleLarge.jpg", "legacy": {"xlarge": "images/2014/12/08/business/08EYE/08EYE-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "1464"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2014/12/08/business/08EYE/08EYE-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/12/08/business/08EYE/08EYE-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-12-08T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Eyes and Eyesight", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Doctors", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Lucentis (Drug)", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Genentech Inc", "name": "organizations", "is_major": "Y", "rank": "4"}, {"value": "Avastin (Drug)", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Macular Degeneration", "name": "subject", "is_major": "N", "rank": "6"}, {"value": "Medicare", "name": "subject", "is_major": "N", "rank": "7"}, {"value": "Conflicts of Interest", "name": "subject", "is_major": "N", "rank": "8"}], "blog": [], "subsection_name": null, "type_of_material": "News"}